melatonin might help, but we're not sure how much is real
In the long human search for relief from persistent pain, a team at the University of Sydney has turned attention to melatonin — a hormone more commonly associated with sleep than suffering. Their synthesis of nine clinical trials suggests that for people living with chronic musculoskeletal conditions like fibromyalgia and osteoarthritis, melatonin may offer pain relief comparable to standard anti-inflammatory drugs, though its advantage over placebo remains statistically uncertain. The findings do not close a chapter so much as open a question worth pursuing with greater rigor.
- Millions of chronic pain sufferers face real limits with NSAIDs — gastrointestinal damage, tolerance, and long-term risk — creating genuine urgency around finding safer alternatives.
- A University of Sydney meta-analysis of 450 participants across nine trials found melatonin reduced pain by nearly 9 points on a 100-point scale compared to all treatments, drawing it level with conventional anti-inflammatories.
- The tension sharpens when melatonin is measured against placebo alone: the reduction drops to 6.76 points and loses statistical significance, leaving open the uncomfortable possibility that expectation, not chemistry, is doing the work.
- Melatonin fared even less convincingly for postoperative pain, suggesting its potential is narrower — most relevant to the grinding, persistent suffering of chronic conditions rather than acute surgical recovery.
- Researchers and clinicians are now pointing toward larger, more rigorous head-to-head trials against NSAIDs before melatonin can be considered a credible addition to standard chronic pain management.
Researchers at the University of Sydney have completed a systematic review asking whether melatonin — a hormone best known for regulating sleep — might also have a meaningful role in managing chronic musculoskeletal pain. Pooling data from nine randomised controlled trials involving around 450 participants taking 3 to 10 milligrams daily, the team examined outcomes across conditions including fibromyalgia, knee osteoarthritis, and neuropathic pain.
Measured against all comparators in the trials, melatonin produced an average pain reduction of 8.96 points on a 100-point scale — a result that places it roughly on par with NSAIDs, the pharmaceutical standard that millions rely on. That comparison carries weight, particularly for patients who have developed side effects or tolerance from long-term anti-inflammatory use. Melatonin is widely available, relatively affordable, and carries far lower gastrointestinal risk.
The picture grows more complicated in direct comparisons with placebo. There, the pain reduction fell to 6.76 points and failed to reach statistical significance — meaning the result could plausibly reflect chance rather than the hormone's true effect. The researchers also reviewed 14 trials on postoperative pain and found melatonin less effective in that acute context, suggesting its usefulness may be specific to the persistent, treatment-resistant nature of chronic conditions.
The study does not claim to settle the question. It is a synthesis of existing evidence, not a definitive trial. But it does point clearly toward what comes next: larger, more rigorous studies comparing melatonin directly to NSAIDs in chronic pain populations. Until that evidence exists, melatonin remains a promising avenue — modest in its current proof, but worth the investigation.
A team of researchers at the University of Sydney has completed a systematic review of melatonin's effectiveness for chronic musculoskeletal pain, and the findings suggest the hormone may work about as well as conventional anti-inflammatory drugs for certain patients. The analysis pooled data from nine randomized controlled trials involving roughly 450 people who took melatonin doses between 3 and 10 milligrams daily to manage long-term pain conditions like fibromyalgia, knee osteoarthritis, and neuropathic pain.
When the researchers compared melatonin against all other treatments in the trials, they found an average pain reduction of 8.96 points on a 100-point scale. That's a meaningful drop—enough that patients might notice relief in their daily lives. The comparison is significant because it suggests melatonin performs similarly to NSAIDs, the standard pharmaceutical approach to musculoskeletal pain that millions of people rely on.
But the picture becomes murkier when the team looked specifically at how melatonin performed against placebo. In those head-to-head comparisons, the pain reduction fell to 6.76 points on the same scale. That's still a reduction, but the difference was not statistically significant—meaning it could have occurred by chance rather than from the drug's actual effect. This distinction matters enormously for how we interpret the findings. A treatment that works as well as an existing drug is promising; a treatment that barely beats a sugar pill is less so.
The researchers also examined 14 trials looking at melatonin for postoperative pain—the acute pain that follows surgery. That body of evidence showed melatonin was less effective in that context, suggesting the hormone may have a narrower window of usefulness. It appears to help more with the grinding, persistent pain of chronic conditions than with the sharp, temporary pain of recovery.
The distinction between chronic and postoperative pain is worth sitting with. Chronic musculoskeletal pain is often resistant to treatment. People with fibromyalgia or long-standing arthritis have often tried multiple approaches and may have developed tolerance to NSAIDs or experienced side effects that make those drugs unsuitable. For them, even a modest alternative might be worth exploring. Melatonin is widely available, relatively inexpensive, and carries fewer gastrointestinal risks than NSAIDs, which can cause ulcers and bleeding with long-term use.
Yet the modest performance against placebo raises a practical question: how much of melatonin's benefit comes from the hormone itself, and how much comes from the ritual of taking a pill, the expectation of relief, or the natural fluctuations of chronic pain? The researchers did not claim to have answered that question definitively. Their work is a synthesis of existing trials, not a definitive proof.
What comes next is clearer. Larger, more rigorous trials comparing melatonin directly to NSAIDs in chronic pain populations would help clarify whether this hormone deserves a place in the standard toolkit. Until then, the Australian analysis suggests melatonin is worth investigating further—but not yet a replacement for established treatments.
Citas Notables
Melatonin showed more promise for chronic musculoskeletal pain than for postoperative musculoskeletal pain— University of Sydney research team
La Conversación del Hearth Otra perspectiva de la historia
Why does melatonin work for chronic pain at all? It's a sleep hormone.
That's the intuitive question. Melatonin does regulate sleep, but it also has anti-inflammatory and antioxidant properties. Chronic pain and poor sleep are deeply linked—pain keeps you awake, and sleep deprivation amplifies pain perception. So melatonin might be working on both fronts.
But the placebo result troubles me. Only 6.76 points better than a sugar pill. That's not much.
It's not. And that's exactly why the researchers were careful about their language. The comparison against all other treatments looks better, but that includes some weak comparators. Against placebo specifically, the signal is weak.
So why publish it at all? Why not wait for stronger evidence?
Because this is a meta-analysis—a synthesis of what we already know. It's useful to ask: what does the existing literature actually show? And the answer is: melatonin might help, but we're not sure how much of that help is real versus expectation.
For someone with fibromyalgia who's exhausted all other options, does this change anything?
It might. If NSAIDs are causing problems, or if sleep is part of the problem, melatonin is cheap and accessible. But they'd be taking it on modest evidence, not strong proof.
What would change your mind? What would make this conclusive?
A large trial—maybe 500 or 1000 people—randomized to melatonin or NSAID, measured over months, with careful tracking of pain and function. That would tell us whether melatonin is genuinely competitive or just a placebo with a good story.